Qube Research & Technologies (QRT)
UTMD icon

Qube Research & Technologies (QRT)’s Utah Medical Products UTMD Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,871
Closed -$364K – 4116
2026
Q1 		$364K Sell
5,871
-9,403
-62% -$592K ﹤0.01% 2826
2025
Q4 		$855K Buy
15,274
+1,786
+13% +$104K ﹤0.01% 2618
2025
Q3 		$849K Buy
13,488
+948
+8% +$56.1K ﹤0.01% 2579
2025
Q2 		$714K Sell
12,540
-728
-5% -$39.6K ﹤0.01% 2581
2025
Q1 		$744K Sell
13,268
-799
-6% -$47.9K ﹤0.01% 2388
2024
Q4 		$865K Buy
14,067
+4,343
+45% +$281K ﹤0.01% 2238
2024
Q3 		$651K Buy
9,724
+4,117
+73% +$279K ﹤0.01% 2185
2024
Q2 		$375K Buy
5,607
+1,004
+22% +$68.3K ﹤0.01% 2231
2024
Q1 		$327K Buy
4,603
+3,590
+354% +$269K ﹤0.01% 2767
2023
Q4 		$85.3K Buy
+1,013
New +$84K ﹤0.01% 3152

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $158M AUM 42.05% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Qube Research & Technologies (QRT)'s UTMD Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Utah Medical Products (UTMD) in Q2 2026, closing a stake of 5,871 shares — an estimated $364K sold.

Qube Research & Technologies (QRT) first reported a position in UTMD in Q4 2023 and held it in 10 quarters. The position peaked at $865K in Q4 2024. 114 funds tracked by Wall St. Rank hold UTMD as of Q2 2026.

  • Qube Research & Technologies (QRT) reported no remaining Utah Medical Products position as of Q2 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 5,871 Utah Medical Products shares in Q2 2026, an estimated $364K.
  • Qube Research & Technologies (QRT) first reported a position in Utah Medical Products in Q4 2023 and held it in 10 quarters.
  • Qube Research & Technologies (QRT)'s Utah Medical Products position peaked at $865K in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.